Forensic Analysis · Medical Devices · as of Nov 9, 2026

Sensus Healthcare, Inc. (SRTS)

A forensic read on Sensus Healthcare, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Safe

Financial health

14.4

Distress distance

Clean

Earnings quality

Forensic signals

-14.9%

ROE

-34.3%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Sensus Healthcare, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 14.4, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by inventory days.

What the filings flag

288d

FY2024→FY2025

Inventory days. Days inventory outstanding moved from 231 to 288 FY2024→FY2025 (against cost of goods sold; inventory +44% vs -10% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.

-26.9%

FY2025

Return on invested capital. Return on invested capital is -26.9% in the latest fiscal year, against -1.1% in FY2023, having run between -26.9% and 19.7% across FY2023–FY2025 with no direction held. After-tax operating profit was ($284,156) in FY2023 and ($8M) in FY2025, with operating income at -1.6% of revenue in FY2023, 19.4% in FY2024 and -37.5% in FY2025. The capital base behind it grew +15% across FY2023–FY2025, from $26M to $30M, while the return fell 25.8 points, so the dollars added over that window earned less than the -1.1% the older base was already earning.

90% of FCF

FY2025

Shareholder returns. Returned $300,000 to shareholders (buybacks + dividends) in FY2025 — 90% of free cash flow. Right at the limit of what free cash flow covers — little room before it's funded by debt or the balance sheet. Counting the $295,000 of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 179%.

Key fundamentals

Latest Revenue$27.5M

Revenue Growth YoY-34.3%

Revenue CAGR (2yr)+6.1%

Net Margin-28.1%

Free Cash Flow$332,000

Return on Equity-14.9%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Sensus Healthcare, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.